BRinging Innovation to cLinical and Laboratory research to end HIV In Africa through New vaccine Technology
Read More
BRinging Innovation to cLinical and Laboratory research to end HIV In Africa through New vaccine Technology
Read More
BRinging Innovation to cLinical and Laboratory research to end HIV In Africa through New vaccine Technology
Read More
Program of research will focus on utilising the existing capacity, scientific talent, and ingenuity in sub-Saharan Africa to advance the HIV vaccine field
Partners in the consortium are from 8 African countries viz. South Africa, Nigeria, Kenya, Mozambique, Tanzania, Uganda, Zambia and Zimbabwe
Mainly female scientists from Africa will lead the discovery, design and testing of HIV vaccine candidates
The BRILLIANT Consortium (BRinging Innovation to cLinical and Laboratory research to end HIV In Africa through New vaccine Technology), is a Cooperative Agreement with the US Agency for International Development and kicked off in September 2023.
BRILLIANT constitutes a multi-disciplinary collaboration with partners and collaborators from Nigeria, Uganda, Kenya, Tanzania, Zimbabwe, Zambia, Mozambique, South Africa and Internationally with the overall objective of developing and evaluating HIV vaccine candidates emanating from the African continent.
We envisage that after 5 years we will have advanced at least one HIV vaccine candidate developed in Africa into early phase clinical trials that are discovery in nature that allow for further iteration and development of promising candidates
Our mission is to harness and catalyze African scientists to contribute to an African-led effective HIV vaccine
To develop a HIV vaccine pipeline that emanates from the African continent
